Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 6

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
 receivables(1,178)(1,350)Operating lease right-of-use assets—(5)Prepaid expenses(3,296)(7,523)Other non-current assets(587)—Trade and other payables16,2908,873Operating lease liabilities(845)(872)Accrued expenses and other current liabilities9,488995Net cash flow used in operating activities(137,213)(68,114)Cash flow from investing activitiesPurchase of short-term marketable debt securities(206,207)(203,335)Proceeds from maturities of short-term marketable debt securities439,145145,414Purchase of property and equipment(35)(344)Net cash flow provided by (used in) investing activities232,903(58,265)Cash flow from financing activitiesProceeds from long-term debt, net of issuance costs73,022—Issuance of Class A Ordinary Shares, net of transaction costs—52,540Stamp duty on capital injection from MoonLake to MoonLake AG—(1,470)Proceeds from options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan48091Proceeds from options exercised under Employee Stock Option Plan100—Net cash flow provided by financing activities73,60251,161Effect of movements in exchange rates on cash held1,018(296)Net change in cash and cash equivalents170,310(75,514)Cash and cash equivalents, beginning of period180,426451,169Cash and cash equivalents, end of period$350,736 $375,655Supplementary disclosure of cash flow information:Cash paid for interest$2,871$—Cash paid for income taxes, net of refunds received$66$4Non-cash operating lease right-of-use assets obtained in exchange for lease obligations$—$555

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

6

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025(Unaudited)

s

Note 1 — Overview of the Company

Corporate InformationMoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. MoonLake Immunotherapeutics is currently a single asset company focused on the development of Sonelokimab (“SLK”), a novel tri-specific IL-17A and IL-17F inhibiting